Company news
Opthea Limited (ASX:OPT) news
Opthea Limited news releases on 6ix. Latest, Jun 2, 2026: Reinstatement to Official Quotation
Press releases & updates
Reinstatement to Official Quotation
June 2, 2026
Appendix 4D and Half Year Report for period 31 Dec 2025
March 1, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
January 29, 2026
Long Term Suspended Entities
January 22, 2026
Investor Update Presentation
December 16, 2025
Opthea Receives A$10.8 million R&D Tax Incentive
October 5, 2025
S&P DJI Announces September 2025 Quarterly Rebalance
September 5, 2025
Preliminary Final Report
August 29, 2025
Corporate Update Investor Call
August 19, 2025
Opthea Provides Corporate Update
August 18, 2025
Continuation of Suspension from Quotation
March 31, 2025
Opthea Announces Decision to Discontinue Wet AMD Trials
March 31, 2025
Opthea Announces COAST Phase 3 Trial Topline Results
March 24, 2025
Voluntary suspension
March 18, 2025
Trading Halt
March 16, 2025
Opthea Announces Phase 2b Wet AMD Publication
March 3, 2025
Opthea Reports Half Year Results and Business Updates
February 28, 2025
Opthea Half Year Financial Report - Appendix 4D
February 27, 2025
Opthea Completes Drug Product PPQ Campaign
February 26, 2025
Opthea Completes COAST Final Week 52 Patient Visit
February 18, 2025
Opthea Investor Day
January 28, 2025
Opthea's Corporate Presentation - Jan 2025
January 13, 2025
Opthea Announces Publication in Diabetic Macular Edema
January 6, 2025
Opthea's Wet AMD Program to be Featured at FLORetina 2024
November 25, 2024
Opthea Received A$15.9 Million R&D Tax Incentive
November 14, 2024
Chair's Address to Shareholders
November 14, 2024
Opthea Corporate Presentation - Oct 2024
October 27, 2024
Opthea EURetina Symposium 2024
September 26, 2024
Opthea Joins the S&P/ASX 300 Index
September 22, 2024
Opthea Announces Completion of Drug Substance Campaign
September 18, 2024
Opthea Corporate Presentation - September 2024
September 8, 2024
S&P DJI Announces September 2024 Quarterly Rebalance
September 6, 2024
Opthea Reports Full-Year Results
August 30, 2024
Opthea Preliminary Final and Annual Report
August 30, 2024
Updated Quarterly Report and Cashflow
August 1, 2024
Opthea Welcomes Retina Leaders to its Medical Advisory Board
July 17, 2024
Security Class Reinstatement to Quotation- OPTOB
July 17, 2024
Opthea Announces Results of Retail Entitlement of A$55.9m
July 14, 2024
Security Class Suspension from Quotation OPTOB
July 10, 2024
Opthea Announces Publication on VEGF- C and D
July 9, 2024
Opthea A$55.0m (US$36.9m) Retail Entitlement Offer Opens
June 18, 2024
Opthea Completes Placement & Institutional Entitlement Offer
June 13, 2024
Opthea - Prospectus 2024
June 12, 2024
Opthea Equity Raise Investor Presentation
June 12, 2024
Opthea Annouces Equity Raise
June 12, 2024
Trading Halt - Accelerated Offer
June 11, 2024
Opthea to Present at Clinical Trials at the Summit Meeting
June 2, 2024
Opthea Completes Enrollment in Phase 3 Clinical Program
May 27, 2024
Opthea Corporate Presentation - April 2024
April 4, 2024
Opthea Key Opinion Leader Even on Sozinibercept
April 3, 2024